TScan Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $52.8M
- Price
- $0.7795
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.43%
- Volume
- 136.2K
About
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Quick stats
Shares outstanding67.8M
Computed float47.9M
Float / shares70.6%
Cash runway (months)9
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001783328
Websitehttps://www.tscan.com
AI Summary
AI-generated1/12
standardneutralearnings
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
TScan Therapeutics dosed the first patient in its pivotal Phase 3 ALLOHA-2 trial evaluating TSC-101 for heme malignancies, with topline data expected mid-2028.
Second quarter revenue was $1.1 million, down from $3.1 million in the prior year, while the net loss narrowed to $30.4 million driven by lower R&D spending.
The company ended the quarter with $100.2 million in cash to fund operations into Q2 2027, though missed debt milestones will trigger loan amortization beginning in Q4 2026.
Red flags
- Missed non-covenant debt milestones triggering amortization in Q4 2026
- Revenue declined year-over-year due to timing
- Cash runway limited to Q2 2027